NEW YORK (GenomeWeb News) – LabCorp has obtained an exclusive license granting it access to MGMT methylation-related IP technology developed by the molecular diagnostics company OncoMethylome Sciences, the companies announced today.

The move will allow LabCorp to do commercial MGMT methylation laboratory testing in the US and Canada, with limited exceptions. OncoMethylome also named LabCorp’s Esoterix Clinical Trials Services Division as one of its preferred subcontractors for clinical trial MGMT methylation testing services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.